Olorinab (APD371)

Drug Candidate for Treatment of Pain

Olorinab (APD371) is an oral, peripherally acting, highly-selective, full agonist of the cannabinoid receptor 2 (CB2). Olorinab is an internally discovered investigational drug candidate that Arena is exploring for development in several indications, with an initial focus on visceral pain associated with gastrointestinal disorders. This compound, through its selectivity for CB2, versus CB1, is designed to provide pain relief without psychoactive adverse effects.

About IBS

Irritable bowel syndrome (IBS) is a common disorder of the gastrointestinal (GI) tract. Signs and symptoms include cramping, abdominal pain, bloating, gas, and predominant constipation (IBS-C) or diarrhea (IBS-D), or mixed (IBS-M). IBS is a chronic condition that needs to be managed long term.  There are approximately 27 million patients in the United States with IBS, with approximately 80% reporting frequently recurring or continuous abdominal pain.


We have completed a randomized, open-label Phase 2a clinical trial to evaluate the safety, tolerability and pharmacokinetics of two dose levels of olorinab for abdominal pain associated with Crohn’s disease.  The CAPTIVATE Phase 2b trial for the treatment of abdominal pain associated with IBS has been initiated.

Drug Candidate Disease Area Target Status Retained Rights
Olorinab (APD371) GI Pain CB2 Agonist Phase 2b ongoing Worldwide

Drug Candidate Olorinab (APD371)
Disease Area GI Pain
Target CB2 Agonist
Status Phase 2b ongoing
Retained Rights Worldwide

Olorinab (APD371) has not been approved by the US Food and Drug Administration or any other regulatory agency.

Last updated as of 8/7/19